Navigation Links
Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25% Annually Over the Next Five Years
Date:3/20/2008

Growth will be driven by an increasing physician acceptance of

electrophysiology ablation as an effective treatment for atrial

fibrillation, according to Millennium Research Group

WALTHAM, Mass., March 20 /PRNewswire/ -- According to Millennium Research Group's Global Markets for Atrial Fibrillation (AF) Treatment Devices 2008 report, over 32,000 electrophysiology (EP) procedures were performed for the treatment of AF in the US in 2007. AF EP procedure volumes will increase at a compound annual growth rate of over 25% from 2008 to 2012.

Growth in procedure volumes will be driven by the increasing physician acceptance of EP ablation as a viable and effective treatment for AF. Over the next several years, these procedures will be used more often over medical therapy than in the past. The introduction of new technology will also support greater procedure volumes through 2012; these new devices will enable physicians to increase the safety, efficiency, and efficacy of EP ablation catheter procedures. By 2012, over 109,000 EP procedures will be performed to treat AF in the US.

"The patient pool that hasn't been treated in this market is huge and growing," says Andrew Wong, Analyst at Millennium Research Group. "Almost 3 million people have atrial fibrillation in the US, but currently only about 100,000 are being treated annually."

The Global Markets for Atrial Fibrillation Treatment Devices 2008 report includes coverage of the AF EP, cardiac rhythm management, and surgical ablation device markets. This report provides coverage of US, Europe, and Japan and all key industry competitors, including Biosense Webster, Boston Scientific, Medtronic, and St. Jude Medical.

About Atrial Fibrillation

AF is a type of cardiac arrhythmia. In AF, the atria of the heart are stimulated by abnormal electrical impulses from the sinoatrial node and malfunctioning atrial tissue, resulting in an irregular and disorganized heart beat. AF can lead to heart failure and has been recognized as a major risk factor for stroke. Increased age and unhealthy lifestyle choices are risk factors in developing AF.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
2. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Hyaluronic Acid Knee Procedures Grow 38% from Q3 2006 to Q3 2007
5. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
6. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
7. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... CO (PRWEB) , ... May 05, 2016 , ... ... diagnostics, is proud to support the National Stroke Association during National Stroke Awareness ... the association’s Facebook and Twitter pages throughout the month. CereScan will donate ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. Offering everything from gourmet cooking ... an experience she won’t forget. , Guests that visit LaJollaCooks4u share an experience ...
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , ... strategic partnership with McGill University . The partnership is designed to advance research ... order to help patients in pain. With the new agreement, researchers at Proove Biosciences ...
(Date:5/4/2016)... , May 4, 2016  Bayer today announced ... compound Stivarga ® (regorafenib) tablets for the ... has met its primary endpoint of a statistically ... RESORCE, evaluated the efficacy and safety of regorafenib ... after treatment with sorafenib. The safety and tolerability ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):